glenmark
A new way for a new world

March 15, 2017

To,
Dy. General Manager
Department of Corporate Services,
Bombay Stock Exchange Ltd.,
P. J. Towers, Dalal Street,
Fort, Mumbai – 400 001.

Ref: Scrip Code: 532296

To,
The Manager – Listing,
National Stock Exchange of India Ltd.,
Plot No. C/1, G Block,
Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051.

Ref: Scrip Name: GLENMARK

Dear Sirs,

Sub:- Clarification relating to an article on Glenmark published in today's edition of Indian Express

In response to an article published by the Indian Express in its today's edition with respect to Glenmark's Ankleshwar plant receiving observations from the USFDA during its inspection in December, 2016.

In this regard, Glenmark would like to state that its Ankleshwar plant has received the EIR (Establishment Inspection Report) yesterday. The EIR is issued by the FDA only if it finds the facility to be deemed acceptable.

This is for your information.

Thanking You.

Yours faithfully,
For Glenmark Pharmaceuticals Ltd.

Harish Kuber
Company Secretary & Compliance Officer

Glenmark Pharmaceuticals Ltd.
Glenmark House, B D Sawant Marg, Andheri (E), Mumbai - 400 099, India
T: 91 22 4018 9999 F: 91 22 4018 9988 CIN No: L24299MH1977PLC019982 W: www.glenmarkpharma.com
Registered office: B/2, Mahalaxmi Chambers, 22 Bhulabhai Desai Road, Mumbai 400 026 E: complianceofficer@glenmarkpharma.com